Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Goldenberg

Showing results (161-170 of 166) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 166 results.
BJUI Compass|April 27, 2022
Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial resultsKevin C Zorn, Mohamed Bidair, Andrew Trainer, et al.
The Canadian Journal of Urology|April 26, 2020
Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year resultsMihir Desai, Mo Bidair, Naeem Bhojani, et al.
Cancer Research|December 21, 2013
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug developmentDong Lin, Alexander W Wyatt, Hui Xue, et al.
The Journal of Urology|September 10, 2021
Reply by AuthorsLauren Folgosa Cooley, Adaeze A Emeka, Travis J Meyers, et al.
The Journal of Urology|September 10, 2021
Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional CohortLauren Folgosa Cooley, Adaeze A Emeka, Travis J Meyers, et al.
HGG Advances|January 7, 2022
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to TreatmentYu Jiang, Travis J Meyers, Adaeze A Emeka, et al.
Pageof 17

Showing results (161-170 of 166) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 166 results.
BJUI Compass|April 27, 2022
Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial resultsKevin C Zorn, Mohamed Bidair, Andrew Trainer, et al.
The Canadian Journal of Urology|April 26, 2020
Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year resultsMihir Desai, Mo Bidair, Naeem Bhojani, et al.
Cancer Research|December 21, 2013
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug developmentDong Lin, Alexander W Wyatt, Hui Xue, et al.
The Journal of Urology|September 10, 2021
Reply by AuthorsLauren Folgosa Cooley, Adaeze A Emeka, Travis J Meyers, et al.
The Journal of Urology|September 10, 2021
Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional CohortLauren Folgosa Cooley, Adaeze A Emeka, Travis J Meyers, et al.
HGG Advances|January 7, 2022
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to TreatmentYu Jiang, Travis J Meyers, Adaeze A Emeka, et al.
Pageof 17